1 completed. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Completed 1 |
Follow CKD-519: new trials by email Literature Review of CKD-519 trials Research Report on CKD-519
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| To Assess the Safety, Efficacy and Tolerability of CKD-519, Administered With HMG-CoA Reductase Inhibitors Atorvastatin 20mg, Atorvastatin 20 mg + CKD-519 50 mg, Atorvastatin 20 mg + CKD-519 100 mg - Dyslipidemias | Phase 2 | Completed | Chong Kun Dang Pharmaceutical | 62 | 2017-03-23 | 2018-11-06 |
Dyslipidemias (1) · Hyperlipidemias (1)
Chong Kun Dang Pharmaceutical (1)
Australia (1)